IDH1, TP53, and ATRX mutations are associated with low-grade astrocytomas collaborate to inhibit SOX2 (a nucleosome-binding pioneer TF acting to make genes accessible to the transcription machinery) and prevent the development of human neural stem cells [90,91]. Here, TP53 is linked to astrocytoma (excluding glioblastoma).